A share price of Lyell Immunopharma Inc [LYEL] is currently trading at $3.01, up 13.16%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The LYEL shares have gain 44.02% over the last week, with a monthly amount glided 28.09%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Lyell Immunopharma Inc [NASDAQ: LYEL] stock has seen the most recent analyst activity on August 28, 2023, when JP Morgan downgraded its rating to a Neutral and also revised its price target to $5 from $15. Previously, Morgan Stanley downgraded its rating to Equal-Weight on November 14, 2022, and dropped its price target to $7. On November 11, 2022, downgrade downgraded it’s rating to Neutral and revised its price target to $7 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $12 on October 17, 2022. Morgan Stanley initiated its recommendation with a Overweight and recommended $25 as its price target on July 12, 2021. JP Morgan started tracking with a Overweight rating for this stock on July 12, 2021, and assigned it a price target of $22. In a note dated July 12, 2021, Goldman initiated an Buy rating and provided a target price of $30 on this stock.
Lyell Immunopharma Inc experienced fluctuations in its stock price throughout the past year between $1.32 and $3.97. Currently, Wall Street analysts expect the stock to reach $9.5 within the next 12 months. Lyell Immunopharma Inc [NASDAQ: LYEL] shares were valued at $3.01 at the most recent close of the market. An investor can expect a potential return of 215.61% based on the average LYEL price forecast.
Analyzing the LYEL fundamentals
Trailing Twelve Months sales for Lyell Immunopharma Inc [NASDAQ:LYEL] were 0.13M which represents -99.97% decline. Gross Profit Margin for this corporation currently stands at -150.75% with Operating Profit Margin at -1902.54%, Pretax Profit Margin comes in at -1804.86%, and Net Profit Margin reading is -2310.02%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -0.42 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.84 points at the first support level, and at 2.67 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.16, and for the 2nd resistance point, it is at 3.32.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Lyell Immunopharma Inc [NASDAQ:LYEL] is 16.07. Further, the Quick Ratio stands at 16.07, while the Cash Ratio is 4.22. Considering the valuation of this stock, the price to sales ratio is 5883.39, the price to book ratio is 1.17.
Transactions by insiders
Recent insider trading involved Klausner Richard, Director, that happened on Aug 15 ’23 when 58020.0 shares were sold.
